APTX Aptinyx Inc. Stock Quote

APTX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.26	Insider Own	3.35%	Shs Outstand	46.98M	Perf Week	4.99%
Market Cap	234.00M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	169.94%	Shs Float	37.10M	Perf Month	8.99%
Income	-52.30M	PEG	-	EPS next Q	-0.25	Inst Own	55.30%	Short Float	5.17%	Perf Quarter	2.56%
Sales	2.50M	P/S	93.60	EPS this Y	-7.10%	Inst Trans	11.86%	Short Ratio	1.93	Perf Half Y	-6.10%
Book/sh	2.34	P/B	1.71	EPS next Y	-1.80%	ROA	-44.60%	Target Price	-	Perf Year	-13.04%
Cash/sh	1.77	P/C	2.25	EPS next 5Y	-	ROE	-46.40%	52W Range	1.60 - 6.47	Perf YTD	15.61%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-58.80%	52W High	-38.18%	Beta	-
Dividend %	-	Quick Ratio	26.50	Sales past 5Y	-	Gross Margin	-	52W Low	150.00%	ATR	0.27
Employees	43	Current Ratio	26.50	Sales Q/Q	-66.70%	Oper. Margin	-	RSI (14)	58.14	Volatility	10.58% 6.87%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	45.10%	Profit Margin	-	Rel Volume	0.66	Prev Close	4.02
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 12 AMC	Payout	-	Avg Volume	995.56K	Price	4.00
Recom	1.80	SMA20	7.65%	SMA50	12.02%	SMA200	10.81%	Volume	658,581	Change	-0.50%

Oct-27-20

Initiated

Piper Sandler

Overweight

$10

Jul-01-20

Initiated

SunTrust

Buy

$15

May-08-20

Initiated

William Blair

Outperform

Apr-29-20

Initiated

H.C. Wainwright

Buy

Sep-12-19

Initiated

Wedbush

Outperform

Aug-13-19

Downgrade

JP Morgan

Neutral → Underweight

Jun-20-19

Initiated

SVB Leerink

Outperform

$12

Jan-17-19

Downgrade

JP Morgan

Overweight → Neutral

Nov-15-18

Initiated

Cantor Fitzgerald

Overweight

$40

Jul-16-18

Initiated

Leerink Partners

Outperform

$35

Jul-16-18

Initiated

JP Morgan

Overweight

$30

Jan-19-21 08:31AM	Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions Business Wire +5.10%
Jan-05-21 08:37AM	Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference Business Wire
Jan-04-21 07:57AM	Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy Business Wire
Dec-21-20 08:30AM	Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-16-20 08:30AM	Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer Business Wire
Dec-07-20 03:25PM	Is APTX A Good Stock To Buy Now? Insider Monkey
Nov-25-20 11:40PM	What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares? Simply Wall St.
Nov-12-20 04:03PM	Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights Business Wire
03:15PM	Aptinyx, Inc. to Host Earnings Call ACCESSWIRE
Nov-10-20 08:37AM	Aptinyx to Participate in Upcoming Virtual Investor Conferences Business Wire +5.23%
Oct-29-20 08:37AM	Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020 Business Wire -8.36%
Oct-27-20 01:35PM	Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate Benzinga
07:00AM	3 Top Healthcare Stocks Under $5 Motley Fool
Oct-26-20 04:01PM	Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option Business Wire
Oct-21-20 10:59PM	Aptinyx Announces Pricing of Public Offering of Common Stock Business Wire -9.20%
04:03PM	Why Aptinyx Stock Sank Today Motley Fool
Oct-20-20 04:01PM	Aptinyx Announces Proposed Public Offering of Common Stock Business Wire +17.35%
10:48AM	Why Aptinyx Stock Is Soaring Today Motley Fool
10:24AM	Aptinyx (APTX) Surges on Promising Stress Disorder Study Data Zacks
09:49AM	Looking Into Aptinyx's Return On Capital Employed Benzinga
09:19AM	Aptinyx stock soars on premarket leading volume after positive trial results of PTSD treatment MarketWatch
08:17AM	The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga
Oct-19-20 04:44PM	Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder Business Wire
Oct-06-20 07:25AM	If You Had Bought Aptinyx (NASDAQ:APTX) Stock A Year Ago, You Could Pocket A 18% Gain Today Simply Wall St. -5.04%
Sep-28-20 08:27AM	Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia Business Wire
Sep-03-20 08:37AM	Aptinyx to Present at Upcoming Virtual Investor Conferences Business Wire
Aug-21-20 09:33AM	Is Aptinyx (NASDAQ:APTX) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Aug-13-20 05:25PM	Aptinyx Inc. (APTX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Aptinyx Reports Second Quarter 2020 Financial Results and Highlights Business Wire
Aug-06-20 12:30PM	Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Aug-04-20 08:37AM	Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire +5.06%
Jul-30-20 04:01PM	Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020 Business Wire +6.78%
Jul-08-20 08:37AM	Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020 Business Wire
Jul-07-20 12:51PM	Are Insiders Buying Aptinyx Inc. (NASDAQ:APTX) Stock? Simply Wall St.
Jul-05-20 10:27PM	Were Hedge Funds Right About Warming Up To Aptinyx Inc. (APTX)? Insider Monkey
Jun-26-20 08:37AM	Aptinyx to be Added to Russell 2000® Index Business Wire -7.53%
Jun-18-20 07:57AM	Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder GlobeNewswire
Jun-16-20 08:37AM	Aptinyx to Present at Upcoming Virtual Investor Conferences GlobeNewswire
May-25-20 11:30AM	Is Aptinyx (APTX) Stock Outpacing Its Medical Peers This Year? Zacks
May-20-20 12:00PM	Aptinyx Inc. (APTX) Moves to Strong Buy: Rationale Behind the Upgrade Zacks
08:49AM	Some Analysts Just Cut Their Aptinyx Inc. (NASDAQ:APTX) Estimates Simply Wall St.
May-18-20 08:19AM	Aptinyx's Shares March Higher, Can It Continue? Zacks
May-16-20 08:44AM	Aptinyx Inc. (NASDAQ:APTX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
May-14-20 05:15PM	Aptinyx Inc. (APTX) Reports Q1 Loss, Lags Revenue Estimates Zacks +6.50%
04:03PM	Aptinyx Reports First Quarter 2020 Financial Results and Highlights GlobeNewswire
May-07-20 12:30PM	Aptinyx Inc (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +5.21%
May-06-20 11:23AM	Top Ranked Momentum Stocks to Buy for May 6th Zacks +12.65%
May-04-20 12:24PM	3 Strong Buy Biotech Stocks Trading Under $10 TipRanks +6.99%
Apr-30-20 08:47AM	Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020 GlobeNewswire
Apr-28-20 09:00AM	The Zacks Analyst Blog Highlights: Airgain, Trilogy Metals, Aptinyx, Veritone and Tufin Software Technologies Zacks
Apr-16-20 12:08PM	Will Aptinyx Continue to Surge Higher? Zacks -7.26%
Apr-03-20 12:00PM	Aptinyx Inc. (APTX) Moves to Buy: Rationale Behind the Upgrade Zacks
Apr-01-20 02:04PM	Earnings Update: Aptinyx Inc. (NASDAQ:APTX) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts Simply Wall St.
Mar-30-20 05:45PM	Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates Zacks +6.91%
04:01PM	Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
03:00PM	Aptinyx, Inc. to Host Earnings Call ACCESSWIRE
Mar-23-20 12:30PM	Earnings Preview: Aptinyx Inc. (APTX) Q4 Earnings Expected to Decline Zacks
Mar-18-20 04:01PM	Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020 GlobeNewswire
Mar-12-20 12:30PM	Earnings Preview: Aptinyx Inc. (APTX) Q4 Earnings Expected to Decline Zacks -11.52%
Feb-19-20 08:37AM	Aptinyx to Present at Upcoming Investor Conferences GlobeNewswire
Jan-30-20 07:07AM	Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinsons Disease GlobeNewswire
Jan-18-20 05:09PM	Notable Insider Buys Last Week: Small-Cap Biotechs Benzinga
Jan-17-20 02:11PM	Largest Insider Trades of the Week GuruFocus.com +27.78%
Jan-14-20 04:01PM	Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option GlobeNewswire
Jan-10-20 09:00AM	Aptinyx Announces Pricing of Public Offering of Common Stock GlobeNewswire -10.69%
07:13AM	The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga
Jan-09-20 04:08PM	Aptinyx Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-08-20 05:28AM	Did You Manage To Avoid Aptinyx's (NASDAQ:APTX) Devastating 80% Share Price Drop? Simply Wall St.
Dec-16-19 07:18AM	Is Aptinyx Inc. (APTX) A Good Stock To Buy? Insider Monkey
Dec-12-19 07:07AM	Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-09-19 04:05PM	Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacologys Annual Meeting GlobeNewswire
Dec-05-19 06:58AM	Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinsons Disease GlobeNewswire
Nov-21-19 02:30PM	IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Nov-19-19 09:40PM	SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Nov-18-19 12:45PM	FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -5.11%
Nov-15-19 03:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX ACCESSWIRE
Nov-14-19 07:57AM	Aptinyx to Present at Upcoming Investor Conferences GlobeNewswire
Nov-13-19 08:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX ACCESSWIRE
Nov-12-19 05:25PM	Aptinyx Inc. (APTX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Aptinyx Reports Third Quarter 2019 Financial Results and Highlights GlobeNewswire
07:27AM	Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions GlobeNewswire
Nov-11-19 08:29PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX GlobeNewswire
Nov-09-19 07:35AM	How Much Of Aptinyx Inc. (NASDAQ:APTX) Do Insiders Own? Simply Wall St.
Nov-05-19 10:32AM	Earnings Preview: Aptinyx Inc. (APTX) Q3 Earnings Expected to Decline Zacks -5.16%
08:07AM	Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 GlobeNewswire
Oct-31-19 07:40PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX ACCESSWIRE
Oct-30-19 09:55AM	FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-29-19 01:42PM	EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Aptinyx Inc. GlobeNewswire -6.21%
01:30PM	FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:07PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX GlobeNewswire
12:30PM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aptinyx Inc. (APTX) ACCESSWIRE
Oct-28-19 06:27PM	Kaskela Law LLC Announces Investigation of Aptinyx Inc. (APTX) on Behalf of Investors GlobeNewswire
07:57AM	Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting GlobeNewswire
Oct-25-19 11:15AM	SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-23-19 12:15PM	2018 SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-22-19 05:20PM	INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-18-19 04:45PM	URGENT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -7.67%
Oct-15-19 02:45PM	FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +13.03%
08:46AM	Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience GlobeNewswire
Oct-14-19 02:20PM	IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -8.09%

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bain Capital Life Sciences Inv	10% Owner	Oct 26	Buy	3.00	3,333,333	9,999,999	8,891,758	Oct 27 05:07 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience